Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.

  Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against AVEO
  Pharmaceuticals, Inc.

Business Wire

LOS ANGELES -- May 15, 2013

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been
filed in the United States District Court for the District of Massachusetts on
behalf of a class (the “Class”) comprising all purchasers of the securities of
AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO) between
January 3, 2012 and May 1, 2013, inclusive (the “Class Period”). Investors who
have losses of $200,000 or more are encouraged to contact the firm for
information concerning a lead plaintiff position in the shareholder lawsuit.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (310) 201-9150 OR (212) 682-5340, TOLL-FREE
AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM. IF YOU INQUIRE BY EMAIL
PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES
PURCHASED.

AVEO engages in discovering, developing, and commercializing targeted cancer
therapies. The Complaint alleges that defendants issued materially false and
misleading statements throughout the Class Period regarding the Phase III
trial design and results for the Company’s drug Tivopath, or tivozanib, for
the treatment of advanced kidney cancer. Specifically, defendants
misrepresented or failed to disclose: (1) that the FDA had recommended that
the Company conduct an additional Phase III trial due to adverse trends in the
Company’s first Phase III trial; (2) the 25% higher rate of death associated
with tivozanib therapy compared to the control drug, sorafenib; (3) that
almost 90% of the patients studied in TIVO-1 were enrolled from sites in
Central and Eastern Europe with inconsistent treatment patterns from those in
the U.S.; and (4) as a result of the foregoing, the Company’s statements were
materially false and misleading at all relevant times.

If you are a member of the Class described above and meet certain legal
requirements, you may move the Court no later than July 8, 2013 to serve as
lead plaintiff. To learn more, or if you purchased AVEO stock prior to the
Class Period, please contact Michael Goldberg, Esquire, of Glancy Binkow &
Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California
90067, or at (310) 201-9150, or contact Gregory Linkh, Esquire, of Glancy
Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York
10168, at (212) 682-5340, Toll Free at (888) 773-9224, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone number
and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
310-201-9150 or 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
212-682-5340 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.